This is consistent with the correlation of versican with tumor initiation and/or progression in a variety of tumors [18-23], as well as the fact that prostate cancer cells have the ability to induce host stromal cells to accumulate versican via a paracrine mechanism [24, 25]. Here, VCAN is linked to prostate cancer.